The Fatty Liver Index Exhibits a Dual Association with Chronic Obstructive Pulmonary Disease: A Machine Learning-Based Analysis of Two Independent Cohorts

Why It Matters

The dual association reveals a metabolic liver‑lung link that can help clinicians identify individuals at risk for COPD and tailor management using a cheap, readily available index.

Key Takeaways

• FLI positively predicts COPD prevalence in US NHANES cohort (OR 1.013).
• Higher FLI associates with milder COPD severity in Chinese patients (OR 0.567).
• Machine‑learning models reached AUC 0.819 for COPD risk prediction.
• FLI shows a non‑linear threshold near 1.045 separating risk patterns.
• FLI is a low‑cost, non‑invasive marker for COPD stratification.

Pulse Analysis

Chronic obstructive pulmonary disease and metabolic‑associated fatty liver disease share inflammatory and lipid‑handling pathways, prompting interest in cross‑organ biomarkers. The fatty liver index, derived from routine lab values and anthropometrics, has emerged as a convenient proxy for hepatic steatosis and broader metabolic dysfunction. By leveraging this metric, researchers aim to capture the systemic milieu that predisposes patients to respiratory decline without adding invasive testing burdens.

In a dual‑cohort analysis, investigators applied three machine‑learning algorithms—LASSO, Boruta, and XGBoost—to isolate the most predictive variables for COPD outcomes. The resulting models incorporated FLI alongside age, smoking status, cardiovascular disease, and liver enzymes, achieving an impressive area under the curve of 0.819 in the NHANES population. Notably, the relationship was not linear: an inflection point near an FLI of 1.045 marked a shift from risk elevation to a protective signal in the Chinese clinical cohort, echoing the “obesity paradox” observed in advanced COPD where higher body reserves may mitigate disease severity.

These findings position FLI as a pragmatic tool for early COPD risk assessment and for gauging disease trajectory among diagnosed patients. Incorporating FLI into routine health checks could enable proactive interventions—such as lifestyle modification or targeted monitoring—especially in populations with high metabolic disease burden. Nevertheless, the retrospective design and reliance on self‑reported COPD in NHANES warrant prospective validation. Future work should explore mechanistic pathways of the liver‑lung axis and test FLI‑guided algorithms in diverse clinical settings to solidify its role in personalized pulmonary care.